Bortezomib and vorinostat in combination with mitoxantrone, dexamethasone, and pegasparaginase during induction and reinduction for infants with acute lymphoblastic leukaemia: a multicentre single-arm
6 days ago
- #chemotherapy
- #acute lymphoblastic leukaemia
- #infant leukaemia
- Study evaluates bortezomib and vorinostat combined with mitoxantrone, dexamethasone, and pegasparaginase for infant acute lymphoblastic leukaemia (ALL).
- Multicentre phase 1/2 study conducted in the USA and Canada, enrolling 50 infants with newly diagnosed ALL.
- Primary endpoint: completion of induction and reinduction without dose-limiting toxicities (DLTs).
- Most common grade 3-4 adverse events included hypertension, infection, fever, neutropenia, and electrolyte imbalances.
- Four treatment-related deaths occurred, all due to infections.
- Infections remain a major cause of morbidity and mortality in this immunocompromised population.
- Funding provided by American Lebanese Syrian Associated Charities, Gateway for Cancer Research, and others.